# BioCryst Pharmaceuticals, Inc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/BioCryst Pharmaceuticals, Inc). ## Overview Biocryst Pharmaceuticals is a U.S.-based biotechnology company focused on rare diseases, with its core commercial product ORLADEYO for hereditary angioedema (HAE). The company combines internal drug discovery with business development to build a pipeline of oral small molecules and injectable protein therapeutics. It has built a commercial infrastructure around ORLADEYO and uses that platform to support additional rare-disease programs. Biocryst also earns collaborative, license, service, and royalty revenue from third-party agreements, making it both a commercial-stage biotech and a development-stage pipeline company. ## Products & services • ORLADEYO (berotralstat) for HAE prevention • Sales of peramivir • Rare-disease drug discovery and development • License, royalty, milestone, and service revenues • Preclinical and clinical product candidates - **Commercial product sales** (80%) — Approved pharmaceutical products sold to specialty pharmacies, distributors, hospitals, and pharmacies, primarily ORLADEYO and peramivir. - **Collaborative and license revenue** (15%) — License fees, milestone payments, service revenue, and royalties from third-party collaborations and out-licensing arrangements. - **Pipeline development programs** (5%) — Internal discovery and clinical-stage rare-disease candidates that are not yet commercial products. - ORLADEYO (berotralstat), an oral once-daily HAE preventive therapy - Peramivir product sales and related royalty revenue - Clinical development of oral small-molecule and injectable protein therapeutics - Preclinical rare-disease programs from internal discovery efforts - Collaborative revenue from licenses, services, milestones, and royalties ## Customers Biocryst sells primarily into the rare-disease treatment ecosystem rather than to broad retail consumers. Its main commercial customer for ORLADEYO in the United States is a single specialty pharmacy that dispenses directly to patients, while outside the U.S. it sells through specialty distributors, hospitals, and pharmacies. The end users are patients with hereditary angioedema and other rare diseases, but purchasing and reimbursement decisions are heavily influenced by payors, specialty pharmacies, and prescribers. The company also serves pharmaceutical and biotech partners through collaboration, licensing, and royalty arrangements. Because the addressable patient populations are small, customer retention, reimbursement access, and physician adoption are especially important to revenue growth. - **U.S. specialty pharmacy channel** (primary) — Buys ORLADEYO for direct-to-patient dispensing in the U.S. and is central to prescription fulfillment and revenue recognition. - **International distributors, hospitals, and pharmacies** (primary) — Purchase ORLADEYO outside the U.S. and support market access in ex-U.S. rare-disease markets. - **Patients with hereditary angioedema** (primary) — The end users of ORLADEYO; demand depends on diagnosis, physician prescribing, adherence, and reimbursement. - **Pharmaceutical collaboration partners** (secondary) — Pay for licenses, services, milestones, or royalties tied to partnered programs and out-licensed assets. - **Healthcare providers and specialty prescribers** (secondary) — Influence adoption of ORLADEYO and other rare-disease therapies through prescribing decisions. - Specialty pharmacies that dispense ORLADEYO to U.S. patients - Specialty distributors outside the U.S. that purchase for resale - Hospitals and pharmacies in ex-U.S. markets - Patients with hereditary angioedema who drive prescription demand - Physicians and HAE specialists who prescribe the therapy - Third-party partners that pay license, milestone, or royalty fees ## Geography Biocryst describes itself as a global biotechnology company, but its commercial base is anchored in the United States. In the U.S., ORLADEYO is generally shipped directly to patients through a single specialty pharmacy, making U.S. market access and reimbursement especially important. Outside the U.S., the company sells through specialty distributors, hospitals, and pharmacies, so international performance depends on local distribution and payor access. The company also references a pending transaction involving the sale of its European ORLADEYO business, which could change its geographic revenue mix and reduce direct exposure to Europe. Manufacturing and third-party supply chain risk are geographically dispersed because the company relies on contract manufacturers and partners rather than a fully integrated internal manufacturing footprint. - United States is the core commercial market for ORLADEYO - Ex-U.S. sales are routed through specialty distributors, hospitals, and pharmacies - European ORLADEYO business is subject to a pending sale transaction - Global operations depend on third-party manufacturers and partners - Geographic mix matters because reimbursement and access differ by market ## Strategy Biocryst’s strategy is to use ORLADEYO as the commercial anchor while expanding into additional rare-disease opportunities. The company is emphasizing structure-guided drug design and internal discovery to generate first-in-class or best-in-class oral and injectable therapies. It also seeks to self-fund operations by increasing profitability from product sales and by monetizing assets through partnerships, royalties, and licensing. A key strategic theme is disciplined capital allocation: focusing on rare diseases where the company believes its commercial infrastructure and scientific capabilities can create durable value. The pending European ORLADEYO transaction suggests a portfolio-shaping approach that prioritizes capital efficiency and U.S.-centric commercialization. - **Expand ORLADEYO commercialization** (short-term) — ORLADEYO is the main revenue engine and supports the company’s commercial infrastructure. - **Advance rare-disease pipeline programs** (medium-term) — Pipeline success is needed to diversify revenue beyond a single commercial product. - **Use partnerships and monetization to fund growth** (medium-term) — Non-dilutive funding can extend runway and reduce dependence on capital markets. - Grow ORLADEYO as the commercial base for the company - Advance rare-disease pipeline assets from internal discovery - Use partnerships and licensing to fund development and reduce risk - Focus on oral small molecules and injectable protein therapeutics - Improve profitability and self-fund operations over time - Optimize the portfolio, including potential asset sales such as Europe ## Risks Biocryst faces the classic risks of a commercial-stage rare-disease biotech: dependence on a small number of products, reimbursement sensitivity, and intense competition from larger pharmaceutical companies. ORLADEYO revenue depends on physician prescribing, patient retention, monthly prescription trends, and third-party payor coverage, so pricing or reimbursement pressure can quickly affect sales. The company also relies on third-party manufacturers and distributors, which creates supply, quality-control, and regulatory-compliance risk that could disrupt product availability. Because its pipeline is still being developed, clinical, regulatory, and commercialization setbacks could delay or eliminate future growth options. In addition, the company’s use of collaboration, royalty, and licensing arrangements exposes it to counterparty performance risk and uncertainty around future milestone realization. - **Dependence on ORLADEYO commercialization** [high] — The company’s revenue and commercial infrastructure are heavily tied to one core HAE product. - **Reimbursement and pricing pressure** [high] — Revenue from product sales depends on favorable pricing and third-party payor coverage. - **Clinical and regulatory failure** [high] — Pipeline assets may not achieve approval or commercial viability, limiting future growth. - **Manufacturing and supply chain disruption** [high] — Biologics and pharmaceutical manufacturing are complex and rely on third parties. - **Competitive pressure** [medium] — Larger competitors may launch safer, more effective, or lower-cost alternatives. - Dependence on ORLADEYO for a large share of commercial value - Reimbursement and pricing pressure can reduce patient access and demand - Competition from better, cheaper, or more convenient therapies - Clinical and regulatory failure risk across pipeline programs - Third-party manufacturing and distribution disruptions - Small rare-disease patient pools limit market size and growth visibility - Counterparty risk in collaborations, royalties, and licensing ## Accounting Biocryst’s most important accounting judgments center on revenue recognition for product sales and collaborative arrangements. Product sales are recognized when control transfers, but the company records reserves for estimated patient non-acceptances and sales reversals, which can move reported revenue between periods. Because ORLADEYO is shipped through specialty channels and the company relies on estimates from specialty pharmacies, quarterly revenue can be affected by timing, returns-like adjustments, and changes in demand. Collaborative revenue from licenses, royalties, milestones, and R&D services is recognized only when performance obligations are satisfied, so the timing of contract milestones can create volatility. The company also records a valuation allowance against substantially all deferred tax assets, reflecting uncertainty about future taxable income and making tax accounting another area where reported results can differ materially from cash economics. - **Product sales reserves and non-acceptance estimates** — Can shift revenue between quarters and affect gross-to-net visibility - **Collaborative and license revenue recognition** — Can create lumpy revenue patterns - **Deferred tax asset valuation allowance** — Affects reported tax expense and effective tax rate - Revenue recognition for ORLADEYO and peramivir product sales - Reserves for patient non-acceptance and sales reversals - Timing of license, milestone, royalty, and service revenue - Quarterly volatility from specialty pharmacy shipment patterns - Valuation allowance on deferred tax assets - Uncertain tax positions and related estimates --- *Last updated: 2026-08-11T04:46:22.630146+00:00*